ANTI-GFP

Anti-AFP antibody produced in rabbit has been used in immunoflorescence.

Anti-AFP antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

Monoclonal antibody for detection of both wild-type and mutant forms of GFP or GFP fusions using:

• Immunoprecipitation
• Western blots
• Immunostaining

Green Fluorescent Protein (GFP) is a spontaneously fluorescent 27kDa protein originally isolated from the jellyfish Aequorea victoria. The molecular cloning of the GFP gene and its subsequent expression in heterologous systems has established GFP as a valuable reporter molecule for in vivo visualization of gene expression events in a wide variety of cell types and organisms. Since, GFP requires no additional substrates or cofactors, GFP′s green fluorescence can be easily detected using blue or UV light after expression in either prokaryotic or eukaryotic cells. In addition, several mutant forms of GFP with unique spectral properties (e.g., enhanced fluorescence signal and shifts in excitation and emission spectra) have been reported.

AFP (α fetoprotein) levels decrease by the second year of birth and its ectopic expression is linked with tumors, such as hepatobastoma, hepatocellular carcinoma (HCC) and yolk sac tumors. Maximum AFP-expressing tumors are of stomach, bile duct or pancreatic origin. AFP-expressing rectal cancer is extremely rare and is usually metastasized to liver with poor prognosis. In patients with chronic hepatitis C, high levels of this protein are linked with increased risk of developing HCC. In patients with metastatic gastric cancer (GC), follow-up of AFP concentrations can help determine early treatment response. For early and intermediate stages of HCC, the addition of this protein and ascites in the BCLC Barcelona Clinic Liver Cancer (BCLC) staging can improvise prognosis determination.